Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37) 37
index medicus (36) 36
oncology (31) 31
melanoma (30) 30
immunotherapy (23) 23
cancer (20) 20
ipilimumab (20) 20
female (18) 18
metastasis (17) 17
male (16) 16
middle aged (15) 15
aged (14) 14
care and treatment (14) 14
melanoma - drug therapy (14) 14
tumors (14) 14
article (13) 13
adult (12) 12
immunology (12) 12
antibodies, monoclonal - therapeutic use (11) 11
metastatic melanoma (11) 11
research (11) 11
therapy (11) 11
hematology, oncology and palliative medicine (10) 10
nivolumab (10) 10
clinical trials (9) 9
drug therapy (9) 9
health aspects (9) 9
melanoma - pathology (9) 9
pd-1 (9) 9
cell lung-cancer (8) 8
cytotoxicity (8) 8
mutation (8) 8
skin neoplasms - pathology (8) 8
abridged index medicus (7) 7
aged, 80 and over (7) 7
antibodies, monoclonal - adverse effects (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
apoptosis (7) 7
ctla-4 blockade (7) 7
melanoma - immunology (7) 7
melanoma - therapy (7) 7
patients (7) 7
pd-1 blockade (7) 7
pembrolizumab (7) 7
safety (7) 7
usage (7) 7
antibodies, monoclonal - administration & dosage (6) 6
blockade (6) 6
chemotherapy (6) 6
expression (6) 6
immune checkpoint (6) 6
melanoma - genetics (6) 6
pd-1 protein (6) 6
research article (6) 6
skin neoplasms - drug therapy (6) 6
treatment outcome (6) 6
tumor microenvironment (6) 6
analysis (5) 5
animals (5) 5
antibody (5) 5
antigens (5) 5
drug dosages (5) 5
guidelines (5) 5
immune response (5) 5
inhibitors (5) 5
lymphocytes (5) 5
lymphocytes t (5) 5
patient outcomes (5) 5
programmed cell death 1 receptor - antagonists & inhibitors (5) 5
solid tumors (5) 5
studies (5) 5
t cells (5) 5
anti-pd-1 (4) 4
antineoplastic agents - adverse effects (4) 4
b7-h1 (4) 4
biomarkers (4) 4
brain neoplasms - secondary (4) 4
cancer therapies (4) 4
clinical trials as topic (4) 4
complications and side effects (4) 4
ctla-4 antigen - antagonists & inhibitors (4) 4
cytokines (4) 4
dendritic cells (4) 4
disease progression (4) 4
disease-free survival (4) 4
drugs (4) 4
improved survival (4) 4
inhibition (4) 4
kaplan-meier estimate (4) 4
kinases (4) 4
medicine, general & internal (4) 4
medicine, research & experimental (4) 4
mek inhibition (4) 4
melanoma - mortality (4) 4
melanoma - secondary (4) 4
neoplasm metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
open-label (4) 4
pd-l1 protein (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
by Weber, Jeffrey S, Dr and D'Angelo, Sandra P, MD and Minor, David, MD and Hodi, F Stephen, MD and Gutzmer, Ralf, MD and Neyns, Bart, MD and Hoeller, Christoph, MD and Khushalani, Nikhil I, MD and Miller, Wilson H, MD and Lao, Christopher D, MD and Linette, Gerald P, MD and Thomas, Luc, MD and Lorigan, Paul, FRCP and Grossmann, Kenneth F, MD and Hassel, Jessica C, MD and Maio, Michele, MD and Sznol, Mario, MD and Ascierto, Paolo A, MD and Mohr, Peter, MD and Chmielowski, Bartosz, MD and Bryce, Alan, MD and Svane, Inge M, MD and Grob, Jean-Jacques, MD and Krackhardt, Angela M, MD and Horak, Christine, PhD and Lambert, Alexandre, PhD and Yang, Arvin S, MD and Larkin, James, FRCP
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Summary Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have... 
Hematology, Oncology and Palliative Medicine | ANTI-PD-1 ANTIBODY | RESPONSE CRITERIA | ONCOLOGY | SAFETY | TOLERANCE | LYMPHOMA | BLOCKADE | PD-1 | CANCER | EXPRESSION | IPILIMUMAB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Male | Melanoma - pathology | CTLA-4 Antigen - immunology | Drug-Related Side Effects and Adverse Reactions - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | CTLA-4 Antigen - therapeutic use | Neoplasm Staging | Paclitaxel - administration & dosage | Medical colleges | Care and treatment | Chemotherapy | Immunotherapy | Immunoglobulin G | Melanoma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
by Robert, Caroline, Prof and Ribas, Antoni, Prof and Wolchok, Jedd D, Prof and Hodi, F Stephen, MD and Hamid, Omid, MD and Kefford, Richard, Prof and Weber, Jeffrey S, Prof and Joshua, Anthony M, PhD and Hwu, Wen-Jen, Prof and Gangadhar, Tara C, MD and Patnaik, Amita, MD and Dronca, Roxana, MD and Zarour, Hassane, Prof and Joseph, Richard W, MD and Boasberg, Peter, MD and Chmielowski, Bartosz, MD and Mateus, Christine, MD and Postow, Michael A, MD and Gergich, Kevin, MA and Elassaiss-Schaap, Jeroen, PhD and Li, Xiaoyun Nicole, PhD and Iannone, Robert, MD and Ebbinghaus, Scot W, MD and Kang, S Peter, MD and Daud, Adil, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Summary Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in... 
Internal Medicine | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | MEK INHIBITION | SAFETY | IMMUNOTHERAPY | MUTATION | BRAF INHIBITORS | IMPROVED SURVIVAL | OPEN-LABEL | PD-1 | Drug Eruptions - etiology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Pruritus - chemically induced | Dose-response relationship (Biochemistry) | Pharmacology, Experimental | Research | Drug therapy | Melanoma | Antigens | Cytotoxicity | Metastasis | Kinases | Drug dosages | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof and Puzanov, Igor, MD and Dummer, Reinhard, Prof and Schadendorf, Dirk, Prof and Hamid, Omid, MD and Robert, Caroline, Prof and Hodi, F Stephen, MD and Schachter, Jacob, Prof and Pavlick, Anna C, MD and Lewis, Karl D, MD and Cranmer, Lee D, MD and Blank, Christian U, MD and O'Day, Steven J, MD and Ascierto, Paolo A, Prof and Salama, April K S, MD and Margolin, Kim A, Prof and Loquai, Carmen, MD and Eigentler, Thomas K, MD and Gangadhar, Tara C, MD and Carlino, Matteo S, MBBS and Agarwala, Sanjiv S, Prof and Moschos, Stergios J, MD and Sosman, Jeffrey A, Prof and Goldinger, Simone M, MD and Shapira-Frommer, Ronnie, MD and Gonzalez, Rene, Prof and Kirkwood, John M, Prof and Wolchok, Jedd D, Prof and Eggermont, Alexander, Prof and Li, Xiaoyun Nicole, PhD and Zhou, Wei, PhD and Zernhelt, Adriane M, BS and Lis, Joy, BSN and Ebbinghaus, Scot, MD and Kang, S Peter, MD and Daud, Adil, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Summary Background Patients with melanoma that progresses on ipilimumab and, if BRAFV600 mutant-positive, a BRAF or MEK inhibitor or both, have few treatment... 
Hematology, Oncology and Palliative Medicine | IMMUNE | RESPONSES | ANTI-PD-L1 ANTIBODY | ONCOLOGY | SAFETY | PD-1 BLOCKADE | BROADENS | NIVOLUMAB | MPDL3280A | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Kaplan-Meier Estimate | Treatment Outcome | Melanoma - pathology | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Aged | Melanoma - mortality | Chemotherapy | Hospitals | Melanoma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
by Margolin, Kim, Prof and Ernstoff, Marc S, MD and Hamid, Omid, MD and Lawrence, Donald, MD and McDermott, David, MD and Puzanov, Igor, MD and Wolchok, Jedd D, MD and Clark, Joseph I, Prof and Sznol, Mario, MD and Logan, Theodore F, MD and Richards, Jon, MD and Michener, Tracy, PharmD and Balogh, Agnes, MS and Heller, Kevin N, MD and Hodi, F Stephen, MD
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 459 - 465
Summary Background Brain metastases commonly develop in patients with melanoma and are a frequent cause of death of patients with this disease. Ipilimumab... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | NUMBER | THERAPY | PROGNOSTIC-FACTORS | STEREOTACTIC RADIOSURGERY | ONCOLOGY | SAFETY | GUIDELINES | BLOCKADE | CONFIDENCE | TEMOZOLOMIDE | Skin Neoplasms - pathology | Prospective Studies | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Melanoma - secondary | Brain Neoplasms - secondary | Melanoma - drug therapy | Adult | Female | Aged | Care and treatment | Metastasis | Research | Oncology, Experimental | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Response assessment criteria for brain metastases: proposal from the RANO group
by Lin, Nancy U, Dr and Lee, Eudocia Q, MD and Aoyama, Hidefumi, Prof and Barani, Igor J, MD and Barboriak, Daniel P, Prof and Baumert, Brigitta G, MD and Bendszus, Martin, Prof and Brown, Paul D, Prof and Camidge, D Ross, MD and Chang, Susan M, Prof and Dancey, Janet, Prof and de Vries, Elisabeth G E, Prof and Gaspar, Laurie E, Prof and Harris, Gordon J, Prof and Hodi, F Stephen, MD and Kalkanis, Steven N, MD and Linskey, Mark E, Prof and Macdonald, David R, MD and Margolin, Kim, Prof and Mehta, Minesh P, Prof and Schiff, David, Prof and Soffietti, Riccardo, Prof and Suh, John H, Prof and van den Bent, Martin J, Prof and Vogelbaum, Michael A, Prof and Wen, Patrick Y, Prof and Response Assessment Neuro-Oncology and Response Assessment in Neuro-Oncology (RANO) group
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. e270 - e278
Summary CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from... 
Hematology, Oncology and Palliative Medicine | GAMMA-KNIFE RADIOSURGERY | BREAST-CANCER | VOLUMETRIC DATA ERRORS | SOLID TUMORS | ONCOLOGY | CLINICAL-TRIALS | GUIDELINES | PHASE-II | Magnetic Resonance Imaging | Brain Neoplasms - secondary | Glioma - secondary | Glioma - pathology | Humans | Brain Neoplasms - pathology | Central Nervous System - pathology | Clinical Trials as Topic | Glioma - epidemiology | Brain Neoplasms - epidemiology | Metastasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
by Lin, Nancy U, Dr and Lee, Eudocia Q, MD and Aoyama, Hidefumi, Prof and Barani, Igor J, MD and Baumert, Brigitta G, Prof and Brown, Paul D, Prof and Camidge, D Ross, MD and Chang, Susan M, Prof and Dancey, Janet, Prof and Gaspar, Laurie E, Prof and Harris, Gordon J, Prof and Hodi, F Stephen, MD and Kalkanis, Steven N, MD and Lamborn, Kathleen R, Prof and Linskey, Mark E, Prof and Macdonald, David R, MD and Margolin, Kim, Prof and Mehta, Minesh P, MD and Schiff, David, Prof and Soffietti, Riccardo, Prof and Suh, John H, Prof and van den Bent, Martin J, Prof and Vogelbaum, Michael A, Prof and Wefel, Jeffrey S, PhD and Wen, Patrick Y, Prof and Response Assessment Neuro Oncol RA and Response Assessment in Neuro-Oncology (RANO) group
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. e396 - e406
Summary Therapeutic outcomes for patients with brain metastases need to improve. A critical review of trials specifically addressing brain metastases shows key... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | PHASE-II TRIAL | NERVOUS-SYSTEM METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | MOTEXAFIN GADOLINIUM | RANDOMIZED-TRIAL | CEREBRAL METASTASES | NEGATIVE BREAST-CANCER | RADIATION-THERAPY | DIAGNOSTIC-ACCURACY | Disease-Free Survival | Magnetic Resonance Imaging | Brain Neoplasms - secondary | Clinical Trials as Topic | Humans | Brain Neoplasms - therapy | Clinical trials | Reports | Metastasis | Brain tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
by Lin, Nancy U, Dr and Wefel, Jeffrey S, PhD and Lee, Eudocia Q, MD and Schiff, David, Prof and van den Bent, Martin J, Prof and Soffietti, Riccardo, Prof and Suh, John H, Prof and Vogelbaum, Michael A, Prof and Mehta, Minesh P, MD and Dancey, Janet, Prof and Linskey, Mark E, Prof and Camidge, D Ross, MD and Aoyama, Hidefumi, Prof and Brown, Paul D, Prof and Chang, Susan M, Prof and Kalkanis, Steven N, MD and Barani, Igor J, MD and Baumert, Brigitta G, Prof and Gaspar, Laurie E, Prof and Hodi, F Stephen, MD and Macdonald, David R, MD and Wen, Patrick Y, Prof and Response Assessment Neuro Oncol RA and Response Assessment in Neuro-Oncology (RANO) group
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. e407 - e416
Summary Neurocognitive function, neurological symptoms, functional independence, and health-related quality of life are major concerns for patients with brain... 
Hematology, Oncology and Palliative Medicine | PROPHYLACTIC CRANIAL IRRADIATION | CELL LUNG-CANCER | PHASE-III TRIAL | BREAST-CANCER | STEREOTACTIC RADIOSURGERY | ONCOLOGY | MOTEXAFIN GADOLINIUM | RANDOMIZED-TRIAL | SINGLE METASTASES | SURGICAL RESECTION | RADIATION-THERAPY | Brain Neoplasms - secondary | Brain Neoplasms - psychology | Humans | Quality of Life | Clinical Trials as Topic | Cognition | Research Design | Clinical trials | Reports | Metastasis | Brain tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiotherapy
by Bang, Andrew, MD and Wilhite, Tyler J., MD and Pike, Luke, MD DPhil and Cagney, Daniel N., MD and Aizer, Ayal A., MD and Taylor, Allison, MA and Spektor, Alexander, MD PhD and Krishnan, Monica, MD and Ott, Patrick A., MD PhD and Balboni, Tracy A., MD MPH and Hodi, F. Stephen, MD and Schoenfeld, Jonathan D., MD MPH
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2017
Abstract Purpose Immune checkpoint inhibitors are increasingly used in the treatment of metastatic cancers and associated with immune-related adverse events... 
Radiology | Hematology, Oncology and Palliative Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
: National Harbor, MD, USA. 9-13 November 2016
by Althammer, Sonja and Steele, Keith and Rebelatto, Marlon and Tan, Tze Heng and Wiestler, Tobias and Schmidt, Guenter and Higgs, Brandon and Li, Xia and Shi, Li and Jin, Xiaoping and Antal, Joyce and Gupta, Ashok and Ranade, Koustubh and Binning, Gerd and Bellmunt, Joaquim and de Wit, Ronald and Vaughn, David J and Fradet, Yves and Lee, Jae Lyun and Fong, Lawrence and Vogelzang, Nicholas J and Climent, Miguel A and Petrylak, Daniel P and Choueiri, Toni K and Necchi, Andrea and Gerritsen, Winald and Gurney, Howard and Quinn, David I and Culine, Stéphane and Sternberg, Cora N and Mai, Yabing and Puhlmann, Markus and Perini, Rodolfo F and Bajorin, Dean F and Sharma, Padmanee and Callahan, Margaret K and Calvo, Emiliano and Kim, Joseph W and de Braud, Filipo and Ott, Patrick A and Bono, Petri and Pillai, Rathi N and Morse, Michael and Le, Dung T and Taylor, Matthew and Spilliopoulou, Pavlina and Bendell, Johanna and Jaeger, Dirk and Chan, Emily and Antonia, Scott J and Ascierto, Paolo A and Hennicken, Delphine and Tschaika, Marina and Azrilevich, Alex and Rosenberg, Jonathan and Levy, Ofer and Chan, Christopher and Cojocaru, Gady and Liang, Spencer and Ophir, Eran and Ganguly, Sudipto and Toporik, Amir and Kotturi, Maya and Kfir, Tal Fridman and Murter, Benjamin M and Logronio, Kathryn and Dassa, Liat and Leung, Ling and Greenwald, Shirley and Azulay, Meir and Kumar, Sandeep and Alteber, Zoya and Pan, Xiaoyu and Machlenkin, Arthur and Benita, Yair and Drake, Andrew W and Chajut, Ayelet and Salomon, Ran and Vankin, Ilan and Safyon, Einav and Hunter, John and Levine, Zurit and White, Mark and Leidner, Rom and Kang, Hyunseok and Haddad, Robert and Segal, Neil H and Wirth, Lori J and Ferris, Robert L and Hodi, F. Stephen and Sanborn, Rachel E and Gajewski, Thomas F and Sharfman, William and McDonald, Dan and Srivastava, Shivani and Gu, Xuemin and Phillips, Penny and Passey, Chaitali and Seiwert, Tanguy and Habtetsion, Tsadik and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 12/2016, Volume 4, Issue S2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
by Hodi, F Stephen, Dr and Chesney, Jason, Prof and Pavlick, Anna C, MD and Robert, Caroline, Prof and Grossmann, Kenneth F, MD and McDermott, David F, MD and Linette, Gerald P, MD and Meyer, Nicolas, Prof and Giguere, Jeffrey K, MD and Agarwala, Sanjiv S, Prof and Shaheen, Montaser, MD and Ernstoff, Marc S, Prof and Minor, David R, MD and Salama, April K, MD and Taylor, Matthew H, MD and Ott, Patrick A, MD and Horak, Christine, PhD and Gagnier, Paul, MD and Jiang, Joel, PhD and Wolchok, Jedd D, Prof and Postow, Michael A, MD
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1558 - 1568
Summary Background Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients... 
Hematology, Oncology and Palliative Medicine | PEMBROLIZUMAB | ONCOLOGY | PLUS IPILIMUMAB | CHEMOTHERAPY | Double-Blind Method | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Nivolumab | Mutation | Melanoma - mortality | Viral antibodies | Medical colleges | Care and treatment | Patient outcomes | Melanoma | Antibodies | Clinical trials | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
by Weber, Jeffrey S, Prof and Gibney, Geoff, MD and Sullivan, Ryan J, MD and Sosman, Jeffrey A, Prof and Slingluff, Craig L, Prof and Lawrence, Donald P, MD and Logan, Theodore F, MD and Schuchter, Lynn M, Prof and Nair, Suresh, MD and Fecher, Leslie, MD and Buchbinder, Elizabeth I, MD and Berghorn, Elmer, BSN and Ruisi, Mary, MD and Kong, George, PhD and Jiang, Joel, PhD and Horak, Christine, PhD and Hodi, F Stephen, Dr
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 943 - 955
Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in... 
Hematology, Oncology and Palliative Medicine | UNTREATED MELANOMA | CTLA-4 | ONCOLOGY | PD-1 | Skin Neoplasms - pathology | Prognosis | Skin Neoplasms - drug therapy | Drug Administration Schedule | Follow-Up Studies | Humans | Ipilimumab | Middle Aged | Male | Survival Rate | Melanoma - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Female | Aged | Neoplasm Staging | Complications and side effects | Medical colleges | Research institutes | Melanoma | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
by Seymour, Lesley, Prof and Bogaerts, Jan, PhD and Perrone, Andrea, MD and Ford, Robert, MD and Schwartz, Lawrence H, Prof and Mandrekar, Sumithra, Prof and Lin, Nancy U, MD and Litière, Saskia, PhD and Dancey, Janet, Prof and Chen, Alice, MD and Hodi, F Stephen, Prof and Therasse, Patrick, MD and Hoekstra, Otto S, Prof and Shankar, Lalitha K, MD and Wolchok, Jedd D, MD and Ballinger, Marcus, PhD and Caramella, Caroline, MD and de Vries, Elisabeth G E, Prof and RECIST Working Grp and RECIST working group
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. e143 - e152
Summary Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | UNTREATED MELANOMA | CARBOPLATIN | PEMBROLIZUMAB | SOLID TUMORS | ONCOLOGY | IMMUNE-RELATED RESPONSE | DOUBLE-BLIND | NIVOLUMAB | COMBINATION | IPILIMUMAB | Neoplasms - therapy | Practice Guidelines as Topic - standards | Humans | Immunotherapy | Response Evaluation Criteria in Solid Tumors | Tumor Burden | Disease Progression | Usage | Chemotherapy | Oncology, Experimental | Analysis | Research | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights